Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVEREST-2: A2B694 and A2B543 in Solid Tumors
NCT06051695Phase 2Recruiting
- Sponsor
- A2 Biotherapeutics
- Start
- Apr 2024
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of A2B694, A2B543 in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), pancreatic cancer (PC), ovarian cancer, sponsored by A2 Biotherapeutics. Started Apr 2024; status: recruiting.
02
Drugs
A2B694A2B543
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)ovarian cancer
Beyond the preview
Go deeper on NCT06051695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06051695.